Status:

RECRUITING

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Atherosclerotic Vascular Disease

Heterozygous Familial Hypercholesterolemia

Eligibility:

All Genders

18-99 years

Brief Summary

This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.

Detailed Description

The objective of the study is to determine the proportion of Atherosclerotic cardiovascular disease (ASCVD) and/or Heterozygous Familial Hypercholesterolemia (HeFH) patients reaching low-density lipop...

Eligibility Criteria

Inclusion

  • Aged ≥ 18 years.
  • Written signed informed consent form (ICF).
  • Patients with a confirmed clinical indication for inclisiran who have received the first dose of inclisiran, following clinical judgement, at least 2 months prior to the inclusion in the study.
  • Available assessment of LDL-C levels (mg/dL) within 6 months before inclisiran initiation. The measurement of LDL-C levels must be done after one month of stable LLT and without any modification from the testing up to inclisiran initiation.
  • Statin-intolerant patients are eligible if they had documented side effects on ≥2 statins, including one at the lowest dose.

Exclusion

  • 1\. Participating in a clinical trial of a treatment that could modify LDL-C levels during the observational period of the study.

Key Trial Info

Start Date :

June 16 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06958315

Start Date

June 16 2025

End Date

December 31 2026

Last Update

December 30 2025

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Novartis Investigative Site

Cadiz, Andalusia, Spain, 11009

2

Novartis Investigative Site

Granada, Andalusia, Spain, 18014

3

Novartis Investigative Site

Huelva, Andalusia, Spain, 21005

4

Novartis Investigative Site

Jaén, Andalusia, Spain, 23007